DEI is emerging triumphant in shareholder battles across corporate America from Coca-Cola to Berkshire Hathaway
At companies ranging from Coca-Cola to Apple, investors asked to vote on anti-DEI resolutions are not biting. · Fortune · bakhtiar_zein—Getty Images

In This Article:

No matter where you stand politically, it’s hard to deny that it’s been a banner year for the anti-DEI movement: President Donald Trump has issued executive orders designed to stamp out diversity practices in both the private and public sector, and several large companies have rolled back their DEI programs.

This culture shift was the backdrop to several recent anti-DEI shareholder votes at companies ranging from Coca-Cola to Apple, as activists tried to ramp up the fight over diversity and inclusion policies. But while anti-DEI proposals have become more common, they are not gaining in popularity. At companies ranging from  Coca-Cola to Apple, investors asked to vote on anti-DEI resolutions are not biting. Across the board, support for these proposals has ranged from only 1% to 2% of voters.

To be sure, that has been true in previous years, too. As a general rule, shareholders rarely vote in favor of politically and socially motivated proposals, preferring to let corporate executives make decisions in such realms. Still, the fact that these proposals have landed with a notable thud in such a pivotal year shows a specific kind of corporate resistance to major politicians and anti-DEI crusaders.

Below is a look at how some DEI proposals have fared so far this proxy season.

Bristol Myers Squibb

Shareholder meeting date: May 6, 2025

The National Center for Public Policy Research (NCPPR), a conservative activist shareholder group, submitted a proposal asking that BMS “cease DEI efforts,” calling the practices discriminatory and suggesting it put the company at risk of discrimination lawsuits. That’s a common argument made in several anti-DEI proposals, with the activists citing the Supreme Court ruling that struck down affirmative action in college admissions as a warning for private sector companies practicing DEI.

But in its proxy statement, Bristol Myers Squibb urged shareholders to reject the NCPPR’s proposal, and the drugmaker’s board explained its point of view on diversity in no uncertain terms: “We value inclusion and prioritize building an inclusive workforce in compliance with applicable non-discrimination laws, as do our shareholders,” it wrote. “We believe our inclusion philosophy leads to greater financial and patient outcomes and generates shareholder value, because it helps drive our strategic goal to reach more patients with our transformative medicines.”

The outcome:  The NCPPR proposal was rejected by 97% of shareholders, with 1% abstaining and 1% supporting the proposal.


Berkshire Hathaway

Shareholder meeting date: May 3, 2025